2024
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024 PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-infectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virus
2022
Attacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programImpact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study
Howell J, Samani A, Mannan B, Hajiev S, Aval L, Abdelmalak R, Tam VC, Bettinger D, Thimme R, Taddei TH, Kaplan DE, Seidensticker M, Sharma R. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances In Gastroenterology 2022, 15: 17562848221100106. PMID: 36199289, PMCID: PMC9527996, DOI: 10.1177/17562848221100106.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseImpact of NAFLDBody mass indexOverall survivalHepatocellular carcinomaLiver diseasePresence of NAFLDMultivariable Cox proportional hazardsMedian body mass indexAdvanced-stage hepatocellular carcinomaGrade 2 hypertensionLower starting doseInternational cohort studySimilar clinical benefitsFatty liver diseaseStage hepatocellular carcinomaCox proportional hazardsLogistic regression modellingStarting doseAdverse eventsCohort studyPrognostic factorsClinical outcomesMass indexClinical benefit
2021
Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study
Wang Z, Budhu AS, Shen Y, Wong LL, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao H, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang H, Lee M, Huang Y, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas CE, Yuan J, Khor CC, Koh W, Risch H, Wang XW, Yu H. Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome‐wide association study. JGH Open 2021, 5: 1363-1372. PMID: 34950780, PMCID: PMC8674550, DOI: 10.1002/jgh3.12682.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseCase-control studyHepatocellular carcinomaSingle nucleotide polymorphismsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionGenetic susceptibilityC virus infectionLong-term alcohol useFatty liver diseaseUS case-control studyBody mass indexMajor risk factorGenome-wide association studiesHCV infectionCohort studyLiver diseaseCigarette smokingMass indexRisk factorsHCC casesVirus infectionGene-environment interactionsUS populationDisease risk
2019
Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis
Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and Mortality of Acute‐on‐Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology 2019, 69: 2150-2163. PMID: 30615211, PMCID: PMC6461492, DOI: 10.1002/hep.30494.Peer-Reviewed Original ResearchConceptsHigh short-term mortalityChronic liver failureShort-term mortalityIncidence rateCompensated cirrhosisLiver failureLiver diseaseLiver functionNonalcoholic fatty liver diseaseMedian bilirubin levelRetrospective cohort studyChronic liver diseaseFatty liver diseaseMajority of patientsVeterans Health AdministrationACLF criteriaACLF incidenceAPASL criteriaHepatitis CCohort studyBilirubin levelsPatient groupAcute insultACLFCirrhosis
2012
Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain
Kerr T, Davidson N, Groszmann R, Iwakiri Y, Taddei T. Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain. Hepatology 2012, 56: 1995-1998. PMID: 23115010, PMCID: PMC3627394, DOI: 10.1002/hep.26088.Peer-Reviewed Original ResearchHMG-CoA reductasePhosphorylation of HMG-CoA reductaseExpression of cholesterol metabolism genesHMG-CoA reductase expressionDysregulated cholesterol metabolismFree cholesterolCholesterol metabolism genesHistological severity of NAFLDMetabolic genesAMP kinaseCoA reductaseLDL receptor expressionCholesterol ester hydrolaseDecreased phosphorylationDisease phenotypeLiver-related mortalitySeverity of NAFLDCholesterol metabolismEster hydrolaseCholesterol synthesisNonalcoholic fatty liver diseaseACAT-2Fatty liver diseaseSirtuin 1Receptor expression